XTLB - XTL BIOPHARMACEUTICALS LTD

0.811
0.036   4.439%

Share volume: 24,008
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$0.78
0.04
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
6.05%
1 Month
-23.49%
3 Months
-4.59%
6 Months
-37.13%
1 Year
-39.70%
2 Year
-10.87%
Key data
Stock price
$0.81
P/E Ratio 
0.00
DAY RANGE
$0.72 - $0.81
EPS 
N/A
52 WEEK RANGE
$0.53 - $2.57
52 WEEK CHANGE
-$38.56
MARKET CAP 
15.203 M
YIELD 
N/A
SHARES OUTSTANDING 
5.449 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.58
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$25,499
AVERAGE 30 VOLUME 
$65,975
Company detail
CEO: Shlomo S. Shalev
Region: US
Website: xtlbio.com
Employees: 8
IPO year: 2005
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.

Recent news